217 W. MAIN STREET, SOMERVILLE, NJ
Other Events
Material disclosure
ZyVersa Therapeutics Enters $1 Million Securities Purchase Agreement
Director Resignation - Robert G. Finizio Steps Down from Board
Reports Third Quarter 2025 Financial Results
Pablo Guzman Resigns as Chief Medical Officer of ZyVersa Therapeutics
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
News
Q1
FY 2025
Q3
Notice of Late Filing for Quarterly Report
Q2
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload